Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial.
The efficacy and safety of sublingual immunotherapy with carbamylated allergoid (allergoid SLIT) is well recognised. Yet, few data concerning its antiinflammatory effects on the respiratory airways are so far available. Thus we decided to evaluate whether it can reduce the allergic inflammation and improve the clinical symptoms in comparison to pharmacotherapy. The study was perspective, controlled and randomised. It was conducted on 56 patients allergic to House Dust Mite with (n=36) or without Parietaria. Thirty-three of them were allocated to SLIT (22 M, 11 F mean age 15 years) and 22 (13 M, 10 F, mean age 21 years) to pharmacotherapy They were followed-up for 1 year. Symptoms and drugs consumption were assessed by monthly diary cards. Bronchial reactivity was investigated at baseline and after a 12-month treatment, through a methacholine (MCh) test. An evaluation of the nasal eosinophils was also performed at the same times. There was a greater reduction of the mean symptom score (p < 0.01) and drug consumption (p < 0.001) in the SLIT than in the control group. MCh PD20 increased only in the SLIT group (p < 0.0005) The reduction of nasal eosinophils was statistically greater (p < 0.05) only in the SLIT group. A 1-year SLIT reduces the allergic symptoms and the respiratory airways inflammation more than pharmacotherapy.